Self-reported Calcium Use in a Cohort of Postmenopausal Women Receiving Osteoporosis Therapy: Results from POSSIBLE US™

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2015 Apr 17

PMID 25876880

Citations 1

Authors

E Barrett-Connor

S W Wade

R W Downs

T Ganiats

M Hochberg

R R Recker

B S Stolshek

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Calcium use was common and remained high among women on osteoporosis therapy. Use of calcium-supplemented pharmacologic therapy increased from 65.1 to 76.0% in these women (mean follow-up, 27.5 months). Over 12 months, calcium discontinuation was fairly similar among women using calcium only (23.7%) and women supplementing pharmacologic therapy with calcium (22.5%).

Introduction: Calcium has an important role in bone health. This study describes calcium use and persistence in a postmenopausal osteoporosis treatment cohort.

Methods: Subject-reported calcium use was analyzed for 3,722 participants of the Prospective Observational Scientific Study Investigating Bone Loss Experience (POSSIBLE US(TM)) who used calcium either as their sole osteoporosis treatment (calcium only) or to supplement pharmacologic osteoporosis therapy (supplementers). Descriptive analyses were conducted. Kaplan-Meier methods were used to estimate the probability of discontinuing calcium therapy, and logistic regression was used to assess associations (age-adjusted odds ratios) between healthy behaviors and calcium use.

Results: At entry, there were 711 calcium-only subjects and 1,960 of 3,011 subjects on pharmacologic osteoporosis therapy also supplementing with calcium (supplementers). The percentage of supplementers increased from 65.1 to 76.0% during follow-up (mean, 27.5 months). During the first 12 months on study, the probability of calcium discontinuation was 23.7% (95 % confidence interval [CI], 20.7 - 27.0) among calcium-only subjects and 22.5% (95% CI, 20.7-24.5) among supplementers. Supplementers who discontinued pharmacologic therapy were more likely to discontinue calcium than supplementers who continued pharmacologic therapy (34.9 versus 14.8%). Overall 54.2% of calcium-only subjects who discontinued calcium and 42.3% of supplementers who discontinued calcium resumed calcium use during follow-up. Regular exercise was positively correlated with calcium use at study entry.

Conclusions: Calcium supplementation in pharmacologically treated subjects increased over time. Persistence with calcium was high. Discontinuation of pharmacologic osteoporosis therapy was associated with an increased likelihood of discontinuing calcium use.

Citing Articles

Evaluating adherence, tolerability and safety of oral calcium citrate in elderly osteopenic subjects: a real-life non-interventional, prospective, multicenter study.

Rondanelli M, Minisola S, Barale M, Barbaro D, Mansueto F, Battaglia S Aging Clin Exp Res. 2024; 36(1):38.

PMID: 38345765 PMC: 10861607. DOI: 10.1007/s40520-024-02696-9.

References

Bolland M, Avenell A, Baron J, Grey A, MacLennan G, Gamble G . Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010; 341:c3691. PMC: 2912459. DOI: 10.1136/bmj.c3691. View

Ringe J, van der Geest S, Moller G . Importance of calcium co-medication in bisphosphonate therapy of osteoporosis: an approach to improving correct intake and drug adherence. Drugs Aging. 2006; 23(7):569-78. DOI: 10.2165/00002512-200623070-00003. View

Brooks R . EuroQol: the current state of play. Health Policy. 1996; 37(1):53-72. DOI: 10.1016/0168-8510(96)00822-6. View

Barrett-Connor E, Ensrud K, Tosteson A, Varon S, Anthony M, Daizadeh N . Design of the POSSIBLE UStrade mark Study: postmenopausal women's compliance and persistence with osteoporosis medications. Osteoporos Int. 2008; 20(3):463-72. DOI: 10.1007/s00198-008-0674-3. View

Xiao Q, Murphy R, Houston D, Harris T, Chow W, Park Y . Dietary and supplemental calcium intake and cardiovascular disease mortality: the National Institutes of Health-AARP diet and health study. JAMA Intern Med. 2013; 173(8):639-46. PMC: 3756477. DOI: 10.1001/jamainternmed.2013.3283. View

Reymondier A, Caillet P, Abbas-Chorfa F, Ambrosi V, Jaglal S, Chapurlat R . MENOPOST--calcium and vitamin D supplementation in postmenopausal osteoporosis treatment: a descriptive cohort study. Osteoporos Int. 2012; 24(2):559-66. DOI: 10.1007/s00198-012-1999-5. View

Van Hemelrijck M, Michaelsson K, Linseisen J, Rohrmann S . Calcium intake and serum concentration in relation to risk of cardiovascular death in NHANES III. PLoS One. 2013; 8(4):e61037. PMC: 3622603. DOI: 10.1371/journal.pone.0061037. View

Tosteson A, Do T, Wade S, Anthony M, Downs R . Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US. Osteoporos Int. 2010; 21(10):1769-80. DOI: 10.1007/s00198-009-1133-5. View

Wang L, Manson J, Sesso H . Calcium intake and risk of cardiovascular disease: a review of prospective studies and randomized clinical trials. Am J Cardiovasc Drugs. 2012; 12(2):105-16. PMC: 3336363. DOI: 10.2165/11595400-000000000-00000. View

10.

Prentice R, Pettinger M, Jackson R, Wactawski-Wende J, LaCroix A, Anderson G . Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study. Osteoporos Int. 2012; 24(2):567-80. PMC: 3557387. DOI: 10.1007/s00198-012-2224-2. View

11.

Moyer V . Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013; 158(9):691-6. DOI: 10.7326/0003-4819-158-9-201305070-00603. View

12.

Bolland M, Grey A, Avenell A, Gamble G, Reid I . Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ. 2011; 342:d2040. PMC: 3079822. DOI: 10.1136/bmj.d2040. View

13.

Bailey R, Dodd K, Goldman J, Gahche J, Dwyer J, Moshfegh A . Estimation of total usual calcium and vitamin D intakes in the United States. J Nutr. 2010; 140(4):817-22. PMC: 2838624. DOI: 10.3945/jn.109.118539. View

14.

Cauley J . The Women's Health Initiative: Hormone Therapy and Calcium/Vitamin D supplementation trials. Curr Osteoporos Rep. 2013; 11(3):171-8. DOI: 10.1007/s11914-013-0150-7. View

15.

Jackson R, LaCroix A, Gass M, Wallace R, Robbins J, Lewis C . Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006; 354(7):669-83. DOI: 10.1056/NEJMoa055218. View

16.

Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Sinigaglia L . Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int. 2006; 17(6):914-21. DOI: 10.1007/s00198-006-0073-6. View

17.

Weiss T, Siris E, Barrett-Connor E, Miller P, McHorney C . Osteoporosis practice patterns in 2006 among primary care physicians participating in the NORA study. Osteoporos Int. 2007; 18(11):1473-80. DOI: 10.1007/s00198-007-0408-y. View

18.

Ross A, Manson J, Abrams S, Aloia J, Brannon P, Clinton S . The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2010; 96(1):53-8. PMC: 3046611. DOI: 10.1210/jc.2010-2704. View

19.

Gahche J, Bailey R, Burt V, Hughes J, Yetley E, Dwyer J . Dietary supplement use among U.S. adults has increased since NHANES III (1988-1994). NCHS Data Brief. 2011; (61):1-8. View

20.

Li K, Kaaks R, Linseisen J, Rohrmann S . Associations of dietary calcium intake and calcium supplementation with myocardial infarction and stroke risk and overall cardiovascular mortality in the Heidelberg cohort of the European Prospective Investigation into Cancer and Nutrition study.... Heart. 2012; 98(12):920-5. DOI: 10.1136/heartjnl-2011-301345. View